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plant, and pulmonary infection with 
M. kansasii developed in 2 recipients 
of lung transplants (5). There is also 
a case report of systemic M. bovis in-
fection developing in a patient with 
relapsing B chronic lymphocytic leu-
kemia after administration of alemtu-
zumab (10).
Although we believe that alem-
tuzumab is responsible for the severe 
immunosuppression that predisposed 
these patients to M. haemophilum in-
fection, other explanations are plau-
sible. For example, patient 1 had re-
ceived rituximab and cyclophosamide 
for 6 months. These drugs, in addition 
to his underlying disease of chromic 
lymphocytic leukemia, may have pre-
disposed him to M. haemophilum in-
fection. However, his lesions did not 
appear until he received alemtuzumab. 
In patient 2, the immunosuppression 
associated with his transplant may 
have predisposed the patient to M. 
haemophilum infection.
This report identifi es M. haemo-
philum as an opportunistic pathogen 
in patients who have received alem-
tuzumab. We recommend that all 
patients who have received at least 1 
dose of alemtuzumab, and who have 
undiagnosed tender skin lesions lo-
cated over the extremities, be evalu-
ated by using appropriate techniques 
to isolate M. haemophilum. Commu-
nication with microbiology laborato-
ry staff concerning appropriate meth-
ods for detection of the organism is 
crucial.
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Prior Evidence of 
Putative Novel 
Rhinovirus Species, 
Australia
To the Editor: Briese et al. (1) are 
to be congratulated for their delineation 
of the global geographic presence of 
human rhinovirus (HRV) strains simi-
lar to those reported in 2006 from one 
third of cases of an otherwise patho-
gen-negative respiratory outbreak in 
New York. Of equal importance is the 
temporal occurrence of these strains. 
Although it is intriguing to suggest, 
on the basis of limited sequence data, 
that these strains were circulating at 
least 2 centuries earlier (1), Briese et 
al. neglect to acknowledge empirical 
evidence that what we now call HRV- 
C strains circulated before 2004–2005. 
Unculturable PCR-positive rhinovi-
ruses were reported in 1993; however, 
more compelling is the fact that sub-
genomic sequence and phylogenetic 
data were reported from Belgium (2), 
Australia (3), and then New York (4). 
The Belgium noncoding sequences 
were reported in 2006 but originated 
from specimens collected in 1998–
1999. Australian coding sequences 
from 2003 to 2004 were assigned, for 
the fi rst time, to a novel clade called 
HRV-A2, refl ecting both their phylo-
genetic isolation and branching from 
the known HRV-A strains (3). 
It can be deduced that NY-041 
and NY-060, strains from the 2004 
New York winter outbreak, are vari-
ants (>98% amino acid identity) of 
the fi rst characterized HRV-A2 strain, 
HRV-QPM (4,5). More recently, we 
proposed that the HRV-A2 strains di-
verged suffi ciently to meet several of 
the International Committee on Taxon-
omy of Viruses criteria for classifying 
a putative new species, HRV-C (6).
It is an exciting time for those in-
terested in rhinoviruses. With increased 
implementation of multiplexed screen-
ing approaches (such as the MassTag 
PCR), or by simply including a specifi c 
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and sensitive PCR for all known strains 
(7), further details of the geographic 
and temporal extent of the neglected 
rhinoviruses should soon be available. 
Better identifi cation may fi nally enable 
accurate characterization of the clini-
cal, economic, and social impact (8) of 
HRV infection.
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In Response: We appreciate the 
enthusiasm for our recent publication 
highlighting the global distribution 
of a long-unrecognized third clade of 
rhinoviruses. Robust, sequence-based 
clock estimates with associated confi -
dence limits indicate that these viruses 
have been circulating for hundreds of 
years (1), consistent with the presence 
of such viruses in historic samples. 
As isolates from various collections 
are analyzed in informative regions 
(e.g., virus protein [VP] 4/2 or VP1), 
we will undoubtedly fi nd examples 
in which human rhinoviruses (HRVs) 
could have been classifi ed as members 
of the new species HRV-C but were 
not because the characteristics that de-
fi ne HRV-C were not yet appreciated 
or because only noncoding sequences 
had been analyzed. Indeed, we antici-
pate that waxing interest in HRVs may 
well lead to the discovery of additional 
clades. 
There has been discussion in the 
fi eld as to whether the novel sequenc-
es represent a sublineage HRV-A2 of 
the classifi ed species HRV-A (2,3), as 
Mackay et al. had proposed, or whether 
they should be considered as represen-
tatives of a third species of HRV (4,5). 
The International Committee on Tax-
onomy of Viruses (ICTV) is charged 
with the recognition and naming of 
taxonomic entities. Thus, we provi-
sionally designated our sequences as a 
novel clade distinct from HRV-A and 
HRV-B (4) and submitted a proposal 
to ICTV with data supporting the rec-
ognition of HRV-C as a third species of 
rhinovirus. The proposal was recently 
approved by the ICTV Study Group 
on Picornaviruses (Europic May 2008 
meeting in Sitges, Spain). Irrespective 
of taxonomic discourse, we agree with 
Mackay and colleagues that molecular 
analyses of as-yet-uncultured HRVs 
are fascinating and have potential to 
reveal unexpected insights into the 
role of HRVs in disease.
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Errata—Vol. 14, No. 9
In Forest Fragmentation as Cause of Bacterial Transmission among Primates, Humans, and Livestock, Uganda (T.L. Gold-
berg et al.), 2 errors occurred. In Table 3, the numerical values are not in the right positions. The corrected table is available from 
www.cdc.gov/EID/content/14/09/1375-T3.htm. In the same article, Figures 3 and 4 were inadvertently reversed. This has also 
been corrected in the online version of the article (available from www.cdc.gov/EID/content/14/9/1375.htm).
In Neurobrucellosis in Stranded Dolphins, Costa Rica (G. Hernández-Mora et al.), the name of co-author Elías Barquero-
Calvo was misspelled. Several other editing changes to the online version of the article (available from www.cdc.gov/eid/
content/14/9/1430.htm) have also been made upon the authors’ request.
In Texas Isolates Closely Related to Bacillus anthracis Ames (L.J. Kenefi c et al.), 3 author names were inadvertently omit-
ted from the submitted article. They are Carla P. Trim, Jodi A. Beaudry, and James M. Schupp; each is from Northern Arizona 
University, Flagstaff, Arizona, USA. The complete author list as it should have appeared on the article: Leo J. Kenefi c, Talima 
Pearson, Richard T. Okinaka, Wai-Kwan Chung, Tamara Max, Carla P. Trim, Jodi A. Beaudry, James M. Schupp, Matthew N. 
Van Ert, Chung K. Marston, Kathy Gutierrez, Amy K. Swinford, Alex R. Hoffmaster, and Paul Keim. The corrected article is 
available online from www.cdc.gov/EID/content/14/9/1494.htm.
In Clindamycin-Resistant Clone of Clostridium diffi cile PCR Ribotype 027, Europe (D. Drudy et al.), the Figure contained 
errors. The correct version appears in the online version of this article (available from www.cdc.gov/EID/content/14/9/1485.
htm) and is reprinted below.
We regret any confusion these errors may have caused.
Figure. Minimal spanning tree of 
23 Clostridium diffi cile isolates. 
In the circles, the individual 
isolates are mentioned. The 
numbers between the circles 
represent the summed tandem 
repeat differences (STRDs) 
between multiple-locus variable-
number tandem-repeat analysis 
types. Straight lines represent 
single-locus variants, dashed 
lines double-locus variants. 
Curved lines represent triple-
locus variants. Two related 
clusters can be discriminated: 
the light gray cluster (isolates 
B1, B4, M246, B6, and M216) 
and the cluster within dotted 
lines (isolates V6–44, V6–142, 
V6–81, 1ML, C1, 4108, V6–35, 
V6–80, L1, 2191cc, C4, C8, 3ML, C44, C37, and 13ML) The isolates in the light gray cluster are sensitive to clindamycin; isolates 
in the cluster surrounded by dashed lines are resistant. Two isolates (M278 and R20291) did not belong to a cluster but were more 
related to the sensitive cluster than to the resistant cluster. Genetically related clusters were defi ned by an STRD <10.
